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The phase I/II trial included nine patients with Stargardt's macular dystrophy and nine with atrophic age related macular degeneration, the leading causes of juvenile and adult blindness in the developed world. No effective treatments are known for either condition, and both eventually lead to blindness.
The participants had one of three different doses of retinal pigment epithelium cells injected into the sub-retinal space of the eye with the worse vision. The study found no evidence of adverse proliferation, rejection, or serious ocular or systemic safety issues related to the transplanted tissue. Adverse events, including inflammation and pigmentation, were thought to be associated with the surgery and immunosuppression rather than the stem cells.
The study's primary endpoints were the safety and tolerability of the treatment. Testing of visual acuity was carried out as a safety measure to monitor for any loss of vision. However, after a median follow-up of 22 months, visual acuity substantially improved in 10 eyes, remained the same or improved in seven eyes, and decreased in one eye. The untreated fellow eyes did not show similar improvements.
The study author was Steven Schwartz, of the Jules Stein Eye Institute in Los Angeles, who commented, "Our results suggest the safety and promise of human embryonic stem cells to alter progressive vision loss in people with degenerative diseases and mark an exciting step towards using human embryonic stem cells for the treatment of various medical disorders requiring tissue repair or replacement." 
